HKSE - Delayed Quote HKD

PuraPharm Corporation Limited (1498.HK)

0.750 +0.010 (+1.35%)
As of April 24 at 2:41 PM GMT+8. Market Open.
Currency in HKD All numbers in thousands
Download
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
412,390.000
448,069.000
659,592.000
601,815.000
Cost of Revenue
187,866.000
185,365.000
236,239.000
231,866.000
Gross Profit
224,524.000
262,704.000
423,353.000
369,949.000
Operating Expense
275,940.000
306,980.000
380,342.000
298,197.000
Operating Income
-51,416.000
-44,276.000
43,011.000
71,752.000
Net Non Operating Interest Income Expense
-23,042.000
-23,708.000
-26,667.000
-26,374.000
Pretax Income
-120,997.000
-119,182.000
-117,192.000
40,217.000
Tax Provision
-3,011.000
1,032.000
4,685.000
8,507.000
Net Income Common Stockholders
-117,986.000
-120,214.000
-121,877.000
31,710.000
Diluted NI Available to Com Stockholders
-117,986.000
-120,214.000
-121,877.000
31,710.000
Basic EPS
-0.30
-0.30
-0.31
0.09
Diluted EPS
-0.30
-0.30
-0.31
0.09
Basic Average Shares
395,056.819
394,584.833
393,732.673
370,845.654
Diluted Average Shares
395,056.819
394,584.833
393,732.673
371,413.339
Total Expenses
463,806.000
492,345.000
616,581.000
530,063.000
Net Income from Continuing & Discontinued Operation
-117,986.000
-120,214.000
-121,877.000
31,710.000
Normalized Income
-103,142.798
-109,157.765
14,834.120
39,599.456
Interest Income
495.000
475.000
360.000
456.000
Interest Expense
23,537.000
24,183.000
27,027.000
26,830.000
Net Interest Income
-23,042.000
-23,708.000
-26,667.000
-26,374.000
EBIT
-97,460.000
-94,999.000
-90,165.000
67,047.000
EBITDA
-55,723.000
-46,338.000
-40,026.000
114,673.000
Reconciled Cost of Revenue
187,866.000
185,365.000
236,239.000
231,866.000
Reconciled Depreciation
41,737.000
48,661.000
50,139.000
47,626.000
Net Income from Continuing Operation Net Minority Interest
-117,986.000
-120,214.000
-121,877.000
31,710.000
Total Unusual Items Excluding Goodwill
-15,222.000
-13,241.000
-83,072.000
-10,006.000
Total Unusual Items
-15,222.000
-13,241.000
-15,726.000
-10,006.000
Normalized EBITDA
-40,501.000
-33,097.000
-24,300.000
124,679.000
Tax Rate for Calcs
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
-378.798
-2,184.765
-13,706.880
-2,116.544
12/31/2020 - 7/8/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade